Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $60.35 | Total: $301.75 |
| 1 | 10 | $51.12 | Total: $511.20 |
| 1 | 25 | $43.31 | Total: $1,082.75 |
| 1 | 50 | $36.92 | Total: $1,846.00 |
| 1 | 100 | $31.95 | Total: $3,195.00 |
Overview
AZD-1656 is a glucokinase activator (GKA) that can cause dose-limiting hypoglycemia in normal animals used in embryofetal development studies and type 2 diabetes.
Chemical Properties
| Molecular Formula | C24H26N6O5 |
| Molecular Weight | 478.5 |
| CAS Numbers | 919783-22-5 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | COC[C@H](C)Oc1cc(Oc2cnc(cn2)C(=O)N2CCC2)cc(c1)C(=O)Nc1cnc(C)cn1 |
Storage and Handling
0C Short Term, -20C Long Term
References
Krentz AJ, et al. Effect of exogenously administered glucagon versus spontaneous endogenous counter-regulation on glycaemic recovery from insulin-induced hypoglycaemia in patients with type 2 diabetes treated with a novel glucokinase activator, AZD1656, and metformin. Diabetes Obes Metab. 2014 Nov;16[11] 1096-101.